<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194309</url>
  </required_header>
  <id_info>
    <org_study_id>1235.9</org_study_id>
    <nct_id>NCT02194309</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine (Free Dose Combination) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, and pharmacokinetics of telmisartan and amlodipine
      following single administration of 40 mg telmisartan/5 mg amlodipine and 80 mg telmisartan/5
      mg amlodipine, and subsequently, following multiple administration of 40 mg telmisartan/5 mg
      amlodipine and 80 mg telmisartan/5 mg amlodipine once daily for 10 days
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate, body temperature)</measure>
    <time_frame>up to 6 days after last administration in multiple dose phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 6 days after last administration in multiple dose phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant changes in laboratory parameters</measure>
    <time_frame>up to 6 days after last administration in multiple dose phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 6 days after last administration in multiple dose phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a four-point scale</measure>
    <time_frame>up to 6 days after last administration in multiple dose phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum measured concentration of the analyte in plasma) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the concentration-time curve of the analyte in plasma) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean residence time of the analyte in the body after oral administration) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in plasma following extravascular administration) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular administration) for several time points</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RA) based on Cmax</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA based on AUC</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration (Cpre) for several time points</measure>
    <time_frame>up to day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24,10</measure>
    <time_frame>24 hours after last administration on day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan low + amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan high + amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan low</intervention_name>
    <arm_group_label>Telmisartan low + amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan high</intervention_name>
    <arm_group_label>Telmisartan high + amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <arm_group_label>Telmisartan low + amlodipine</arm_group_label>
    <arm_group_label>Telmisartan high + amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male volunteers according to the following criteria:

          1. No finding deviating of clinical relevance and no evidence of a clinically relevant
             concomitant disease based upon a complete medical history, including the physical
             examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead ECG,
             clinical laboratory tests

          2. Age ≥20 and Age ≤35 years

          3. Body weight ≥50 kg

          4. Body mass index (BMI) ≥17.6 and BMI ≤26.4 kg/m2

          5. Signed and dated written informed consent before admission to the trial

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          3. Chronic or relevant acute infections

          4. Any clinical relevant findings of the laboratory test deviating from normal

          5. Positive result for either hepatitis B surface antigen (HBsAg), anti hepatitis C virus
             (HCV) antibodies, syphilitic test or human immunodeficiency virus (HIV) test

          6. History of surgery of gastrointestinal tract (except appendectomy)

          7. History of relevant orthostatic hypotension (mean standing systolic blood pressure
             (SBP) varied by ≥20 mmHg from mean supine SBP or mean standing diastolic blood
             pressure (DBP) varied by ≥10 mmHg from mean supine DBP), fainting spells or blackouts

          8. History of hepatic dysfunction (e.g., biliary cirrhosis, cholestasis)

          9. History of serious renal dysfunction

         10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary
             kidney

         11. History of cerebrovascular disorder

         12. History of hyperkalemia

         13. Known hypersensitivity to any component of the formulation, or to any other
             Angiotensin Receptor Blocker (ARB), angiotensin converting enzyme or dihydropyridine

         14. Intake of drugs with a long half-life (≥24 hours) within at least one month or less
             than 10 half-lives of the respective drug before administration or during the trial

         15. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 7 days before administration or
             during the trial

         16. Participation in another trial with an investigational drug within 4 months or 6
             half-lives of the investigational drug before administration

         17. Smoker (≥20 cigarettes/day)

         18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous
             (equivalent to 540 mL) of sake)

         19. Drug abuse

         20. Blood donation (more than 100 mL within 4 weeks before administration or during the
             trial)

         21. Excessive physical activities (within 1 week before administration or during the
             trial)

         22. Intake of alcohol within 2 days before administration

         23. Inability to comply with dietary regimen of trial centre

         24. Intake of any drugs/supplements with ingredient of hypericum perforatum (citrus
             fruits, Sevilla orange) within 5 days prior to administration

         25. Inability to refrain from smoking on trial days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

